Loading data for IOVA — first visit, this takes a few seconds.

알림

Iovance Biotherapeutics I... (IOVA)

NasdaqGM: IOVA · 실시간 가격 · USD

7.12

+0.02 (0.28%)

종가 기준: Aug 19, 2026, 2:59 PM

0.28% (1D)

데이터 없음

매수호가	3.76
시가총액	3.53B
매출 (ttm)	324.97M
순이익 (ttm)	-289.52M
베타	0.70
EPS (ttm)	-0.69
P/E (ttm)	n/a
선행 P/E	-29.28
P/B (ttm)	4.79
P/S (ttm)	10.85
Earnings Date	Nov 5, 2026

매도호가	4.98
거래량	3,253,621
평균 거래량 (20일)	15,975,932
시가	7.00
전일 종가	7.10
일중 범위	6.98 - 7.31
52주 범위	1.76 - 7.31
애널리스트	n/a
목표주가	n/a
배당	n/a
배당락일	n/a

IOVA 소개

Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally. The company offers Amtagvi, an individualized T cell therapy for solid tumor cancer and for the treatment of adult patients with previously treated advanced, or unresecta...

[더 보기]

산업 Biotechnology

섹터 Healthcare

IPO 일자 Oct 15, 2010

직원 수 975

상장 거래소 NasdaqGM

티커 IOVA

웹사이트 https://www.iovance.com

전체 기업 정보

재무 실적

2025년 Iovance Biotherapeutics의 매출은 263.5M로, 전년 164.07M 대비 60.6% 증가했습니다. 순이익은 -390.98M로, 5.05% 증가했습니다.

재무제표

어닝 서프라이즈

Iovance Biotherapeutics가 Aug 6, 2026에 분기 실적을 발표했습니다:

매출 $99.31M 예상치 하회 $0, 및 65.65% 전년 대비 성장.

EPS -0.11 예상치 상회 0.02, 및 66.67% 전년 대비 성장.

다음 실적 발표

Iovance Biotherapeutics Inc.의 실적 발표 예정일은 Nov 5, 2026, 장 시작 전입니다.
애널리스트 예상 매출은 ... 업그레이드

뉴스

3일 전 · Simply Wall St.

Is Iovance Biotherapeutics (IOVA) Undervalued As Q2 Earnings Reaffirm Revenue Guidance?

Why Iovance Biotherapeutics stock is back in focus after Q2 earnings Iovance Biotherapeutics (IOVA) is back on investor radars after its second quarter 2026 earnings. The company reported higher reven...

6일 전 · Motley Fool

Iovance (IOVA) Q2 2026 Earnings Call Transcript

Record Amtagvi revenue and gross margins signal strong commercial momentum in cell therapy.

1주 전 · Motley Fool

Iovance Biotherapeutics Stock Soars After the Company Posts Strong Q2 Earnings. Is It Heading Even Higher?

The healthcare stock is now up more than 130% this year.

1주 전 · Barrons.com

Replimune Wins FDA Skin Cancer Drug Approval on Third Try. Why the Stock Is Tumbling.

Replimune secures FDA approval for Tudriqev on its third attempt, making it the company’s first product on the market.

1주 전 · Zacks

Does Iovance Biotherapeutics (IOVA) Have the Potential to Rally 28.02% as Wall Street Analysts Expect?

The mean of analysts' price targets for Iovance Biotherapeutics (IOVA) points to a 28% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement ...

2 페이지 중 1